The future of skin cancer treatment is now. Stay ahead of the curve with our library of informational blogs.
Nearly 900,000 cases of non-melanoma skin cancer are treated via Mohs micrographic surgery each year in the United States. While Mohs surgery remains the gold standard for many cases, advancements in low-energy radiation delivery have…
While surgical excision and Mohs surgery will continue to be foundational treatment options for patients with non-melanoma skin cancer (NMSC) and keloids, clinical innovation is actively expanding the modern dermatologist’s therapeutic options. Advanced modalities like…
The intersection of technological innovation and patient experience continues to redefine modern healthcare. Over the past several decades, procedural medicine has evolved through the development of non-invasive treatment modalities. Parallel to advancements in medical devices…
Introducing Superficial Radiotherapy (SRT) into your practice is an effective way to expand non-surgical treatment options. A successful launch demands a look at several core areas of your workflows and operations. From patient experience and…
Basal cell carcinoma (BCC) represents most of the estimated 5+ million non-melanoma skin cancer (NMSC) cases diagnosed annually in the United States. While surgical excision and Mohs micrographic surgery have long served as primary interventions,…